Working… Menu

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00272480
Recruitment Status : Completed
First Posted : January 6, 2006
Last Update Posted : August 25, 2021
Information provided by (Responsible Party):
Imperial College London

Brief Summary:
To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I

Condition or disease Intervention/treatment Phase
HTLV-I-associated Myelopathy Drug: Zidovudine/lamivudine Drug: Placebos Phase 2 Phase 3

Detailed Description:
Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by 6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints: virological and immunological

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
Actual Study Start Date : November 8, 1999
Actual Primary Completion Date : July 30, 2002
Actual Study Completion Date : July 30, 2002

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo in HAM/TSP 24
Drug: Placebos
Active Comparator: Zidvoudine plus lamivudine
Zidvoudine plus lamivudine in HAM/TSP 24
Drug: Zidovudine/lamivudine

Primary Outcome Measures :
  1. Timed walk [ Time Frame: 6 months ]
    Time taken to walk 13m

  2. Osame's Motor Disability Score [ Time Frame: 6 months ]
    0 - 4 (Unaided walk), 5 - 8 (Needs aid to walk), 9 - 13 (Unable to walk)

  3. Pain score [ Time Frame: 6 months ]
    11 point Visual Analogue Scale 0 = no pain, 10 = worse pain

  4. Urinary frequency [ Time Frame: 6 months ]
    Number of times passing urine during the daytime

  5. HTLV-1 proviral load [ Time Frame: 6 months ]
    The number of copies of HTLV DNA in 100 peripheral blood mononuclear cells

Secondary Outcome Measures :
  1. CD25% [ Time Frame: 6 months ]
    Expression of CD25 on T-cells

  2. HLA-DR% [ Time Frame: 6 months ]
    Expression of HLA-DR on T-cells

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HTLV-I-associated myelopathy

Exclusion Criteria:

  • prior exposure to zidovudine or lamivudine on disease modifying therapy
  • under age 16

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00272480

Layout table for location information
United Kingdom
Imperial College
London, United Kingdom, W2 1PG
Sponsors and Collaborators
Imperial College London
Layout table for investigator information
Principal Investigator: Graham P Taylor, FRCP Imperial College London
Publications of Results:
Other Publications:
Taylor GP et al The Bridge Study - A double-blind, placebo controlled trial of zidovudine plus lamivudine for the treatment of patients with HTLV-I-associated myelopathy AIDS Research and Human Retroviruses 2003;19 (suppl 1) #O23

Layout table for additonal information
Responsible Party: Imperial College London Identifier: NCT00272480    
Other Study ID Numbers: BRIDGE1.0
First Posted: January 6, 2006    Key Record Dates
Last Update Posted: August 25, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Imperial College London:
HTLV-I-associated myelopathy
antiretroviral therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Paraparesis, Tropical Spastic
Spinal Cord Diseases
Bone Marrow Diseases
Central Nervous System Diseases
Nervous System Diseases
Hematologic Diseases
Central Nervous System Infections
HTLV-I Infections
Deltaretrovirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Anti-Retroviral Agents